Thomas Jefferson University

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.
One or more keywords matched the following properties of Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.
PropertyValue
has major subject area list Antibodies, Monoclonal; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Immunotherapy; Liver; Neoplasms
information resource reference Zarrabi K, Wu S. Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. Oncology. 2018; 94(5):259-273.
label Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.
Search Criteria
  • Immunotherapy